Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2009 Aug 12

PMID 19667269

Citations 52

Authors

Matthew R Cooperberg

Shiro Hinotsu

Mikio Namiki

Kazuto Ito

Jeanette Broering

Peter R Carroll

Hideyuki Akaza

Affiliations

Soon will be listed here.

Abstract

Purpose: Prostate cancer epidemiology has been marked overall by a downward risk migration over time. However, in some populations, both in the United States and abroad, many men are still diagnosed with high-risk and/or advanced disease. Primary androgen deprivation therapy (PADT) is frequently offered to these patients, and disease risk prediction is not well-established in this context. We compared risk features between large disease registries from the United States and Japan, and aimed to build and validate a risk prediction model applicable to PADT patients.

Methods: Data were analyzed from 13,740 men in the United States community-based Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry and 19,265 men in the Japan Study Group of Prostate Cancer (J-CaP) database, a national Japanese registry of men receiving androgen deprivation therapy. Risk distribution was compared between the two datasets using three well-described multivariable instruments. A novel instrument (Japan Cancer of the Prostate Risk Assessment [J-CAPRA]) was designed and validated to be specifically applicable to PADT patients, and more relevant to high-risk patients than existing instruments.

Results: J-CaP patients are more likely than CaPSURE patients to be diagnosed with high-risk features; 43% of J-CaP versus 5% of CaPSURE patients had locally advanced or metastatic disease that could not be stratified with the standard risk assessment tools. J-CAPRA--scored 0 to 12 based on Gleason score, prostate-specific antigen level, and clinical stage--predicts progression-free survival among PADT patients in J-CaP with a c-index of 0.71, and cancer-specific survival among PADT patients in CaPSURE with a c-index of 0.84.

Conclusion: The novel J-CAPRA is the first risk instrument developed and validated for patients undergoing PADT. It is applicable to those with both localized and advanced disease, and performs well in diverse populations.

Citing Articles

Androgen receptor and osteoglycin gene expression predicting prognosis of metastatic prostate cancer.

Kameda T, Sugihara T, Obinata D, Oshima M, Yamada Y, Kimura N Sci Rep. 2024; 14(1):30654.

PMID: 39730360 PMC: 11680600. DOI: 10.1038/s41598-024-74443-z.

Predictive model of castration resistance in advanced prostate cancer by machine learning using genetic and clinical data: KYUCOG-1401-A study.

Shiota M, Nemoto S, Ikegami R, Tatarano S, Kamoto T, Kobayashi K BJC Rep. 2024; 2(1):69.

PMID: 39516672 PMC: 11523954. DOI: 10.1038/s44276-024-00093-3.

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.

Crawford E, Bryce A, Hussain M, Agarwal N, Beltran H, Cooperberg M JU Open Plus. 2024; 2(4).

PMID: 38774466 PMC: 11108024. DOI: 10.1097/ju9.0000000000000137.

Predictive Models for Assessing Patients' Response to Treatment in Metastatic Prostate Cancer: A Systematic Review.

Lawlor A, Lin C, Rivas J, Ibanez L, Abad Lopez P, Willemse P Eur Urol Open Sci. 2024; 63:126-135.

PMID: 38596781 PMC: 11001619. DOI: 10.1016/j.euros.2024.03.012.

The Geriatric Nutritional Risk Index Predicts Prognosis in Japanese Patients with LATITUDE High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Multi-Center Study.

Naiki T, Takahara K, Watanabe H, Nakane K, Sugiyama Y, Koie T Cancers (Basel). 2023; 15(22).

PMID: 38001593 PMC: 10670086. DOI: 10.3390/cancers15225333.

References

Kattan M, Eastham J, Stapleton A, Wheeler T, Scardino P . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90(10):766-71. DOI: 10.1093/jnci/90.10.766. View

Albertsen P, Hanley J, Fine J . 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293(17):2095-101. DOI: 10.1001/jama.293.17.2095. View

Tsai H, DAmico A, Sadetsky N, Chen M, Carroll P . Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99(20):1516-24. DOI: 10.1093/jnci/djm168. View

Weight C, Klein E, Stephen Jones J . Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer. 2008; 112(10):2195-201. DOI: 10.1002/cncr.23421. View

Krupski T, Smith M, Lee W, Pashos C, Brandman J, Wang Q . Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004; 101(3):541-9. DOI: 10.1002/cncr.20388. View

Naito S, Kuroiwa K, Kinukawa N, Goto K, Koga H, Ogawa O . Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the.... J Urol. 2008; 180(3):904-9. DOI: 10.1016/j.juro.2008.05.047. View

Akaza H . Current status and prospects of androgen depletion therapy for prostate cancer. Best Pract Res Clin Endocrinol Metab. 2008; 22(2):293-302. DOI: 10.1016/j.beem.2008.01.010. View

Keating N, OMalley A, Smith M . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24(27):4448-56. DOI: 10.1200/JCO.2006.06.2497. View

Cooperberg M, Broering J, Litwin M, Lubeck D, Mehta S, Henning J . The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004; 171(4):1393-401. DOI: 10.1097/01.ju.0000107247.81471.06. View

10.

Cooperberg M, Pasta D, Elkin E, Litwin M, Latini D, Du Chane J . The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005; 173(6):1938-42. PMC: 2948569. DOI: 10.1097/01.ju.0000158155.33890.e7. View

11.

Cooperberg M, Lubeck D, Mehta S, Carroll P . Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003; 170(6 Pt 2):S21-5. DOI: 10.1097/01.ju.0000095025.03331.c6. View

12.

. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol. 2005; 12(1):46-61. DOI: 10.1111/j.1442-2042.2004.00984.x. View

13.

Lu-Yao G, Albertsen P, Moore D, Shih W, Lin Y, DiPaola R . Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008; 300(2):173-81. PMC: 2645653. DOI: 10.1001/jama.300.2.173. View

14.

Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K . Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int. 2006; 98(3):573-9. DOI: 10.1111/j.1464-410X.2006.06349.x. View

15.

Shariat S, Karakiewicz P, Roehrborn C, Kattan M . An updated catalog of prostate cancer predictive tools. Cancer. 2008; 113(11):3075-99. DOI: 10.1002/cncr.23908. View

16.

Harrell Jr F, Lee K, Mark D . Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361-87. DOI: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4. View

17.

Stephenson A, Scardino P, Eastham J, Bianco Jr F, Dotan Z, Fearn P . Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006; 98(10):715-7. PMC: 2242430. DOI: 10.1093/jnci/djj190. View

18.

DAmico A, Whittington R, Malkowicz S, Schultz D, Blank K, Broderick G . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11):969-74. DOI: 10.1001/jama.280.11.969. View

19.

Nguyen P, Chen M, Catalona W, Alexander B, Roehl K, Loeb S . Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer. 2008; 113(11):3146-52. DOI: 10.1002/cncr.23926. View

20.

Shahinian V, Kuo Y, Freeman J, Orihuela E, Goodwin J . Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005; 103(8):1615-24. DOI: 10.1002/cncr.20955. View